The ubiquitin ligase RNF2 stabilizes ERα and modulates breast cancer progression.

ABSTRACT: Estrogen receptor α (ERα) is the most common clinical marker used for breast cancer prognosis and the classification of breast cancer subtypes. Clinically, patients with estrogen receptor-positive breast cancer can receive endocrine therapy. However, resistance to endocrine therapy has become an urgent clinical problem. A large number of previous studies have proven that posttranslational modification of the estrogen receptor is significantly related to endocrine therapy resistance. RNF2 is a member of the RING finger protein family that functions as an E3 ubiquitin ligase. Several studies have clarified that RNF2 is a critical regulator of ERα transcriptional regulation. In our current study, we identified RNF2 as an important posttranslational modification regulator of the estrogen recep

SUBMITTER: Yuan L 

PROVIDER: S-EPMC9813066 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature